Can a simple blood test predict brain bleed risk in cavernous malformation patients?
NCT ID NCT01764529
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine that can bleed, causing strokes, seizures, and headaches. This study follows people with an inherited form of CCM to identify factors—such as genetics, gut microbiome, and blood markers—that influence disease severity and progression. The goal is to find measurable outcomes and biomarkers that could help select high-risk patients and monitor drug response in future clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify blood biomarkers and other factors that predict which patients are at highest risk of bleeding, helping to design future treatment trials.
- What could go wrong
- This is an observational study, not a treatment trial, so it will not directly test any therapy. The findings may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
789 people
The number who actually took part.
- Started
-
Apr 2010
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population includes individuals who carry the diagnosis of familial cerebral cavernous malformation (CCM), both symptomatic and asymptomatic.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individual has a CCM mutation confirmed through DNA testing, or * Individual meets 2 or more of the following clinical criteria: 1. Clinical diagnosis of CCM 2. Multi-focal CCMs on MRI 3. Family history of CCM Exclusion Criteria: 1. Individuals who are incarcerated 2. Individuals who are homeless 3. Unable or unwilling to sign the informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cavernous angioma, familial are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alliance to Cure Cavernous Malformation
Charlottesville, Virginia, 22901, United States
-
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Cincinnati Children's Hospital, Division of Pediatric Neurosurgery, Cerebrovascular Program
Cincinnati, Ohio, 45229, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Chicago, Medicine and Biological Sciences
Chicago, Illinois, 60637, United States
-
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87131, United States